MedPlus Health Services
- Market cap
- ₹ 7,182 Cr.
- P/E
- 34x
- P/B
- 3.61x
- 52-week range
- 576.3 – 1,022.2
- ROE
- 12%
- ROCE
- 13%
- Dividend yield
- 0%
- Debt / equity
- 0.72
- Sector
- Retailing
- Industry
- Pharmacy Retail
- Listed on
- NSE, BSE
About
MedPlus Health Services Limited is an India-based company. The Company is primarily engaged in retail trading of medicines and general items, wholesale cash and carry and pathological laboratory testing services, wholesale trading and manufacturing of pharmaceutical products, fast-moving consumer goods and beauty products. It operates through three segments: Retail, Diagnostics, and Others. The Retail segment is engaged in trading pharmaceuticals and general items through its retail stores and online platform. The Diagnostics segment includes diagnostic services, pathological services, and laboratory testing services. The other segment includes the insurance broking business. Its products include Pharmaceutical and wellness products and Fast-moving consumer goods (FMCG). Its omni-channel platform enables the Company to service its customers through its stores, as well as its online channels. Its e-commerce portals include MedPlus Mart, MedPlus Lens, and MedPlus Labs.
Quick check
The five things to look at first. Open one for more.
Latest announcements
Exchange filings and their impact on the company.
- Q2 revenue up 21% YoY to Rs 2,037 cr with diagnostics turning profitable, but PAT flat at Rs 56 cr as expansion costs offset growth.
MedPlus reported Q2 FY27 consolidated revenue of Rs 2,037 crore, up about 21% from a year ago, and net profit of Rs 56 crore, broadly flat year-on-year but up sharply from Rs 33 crore in Q1. Retail grew 21% while diagnostics grew 23% and turned clearly profitable with Rs 4.9 crore segment profit. The board also allotted 19,095 shares under its ESOP plan, which has no material dilution.
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 27 Oct 2026 | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 21 Jul 2026 | Financial Results | Intimation of Board Meeting under Regulation 29 of SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015 ("SEBI LODR") |
| 29 May 2026 | Financial Results | Intimation of Board Meeting under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR ") |
| 20 May 2026 | Financial Results/Other business matters | Revised Intimation of Board Meeting under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR ") |
| 30 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 31 Oct 2025 | Financial Results | To consider and approve the financial results for the quarter and half year ended September 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,409 | 1,441 | 1,490 | 1,489 | 1,576 | 1,561 | 1,510 | 1,543 | 1,679 | 1,806 | 1,864 | 1,880 |
| Expenses | 1,324 | 1,350 | 1,385 | 1,395 | 1,452 | 1,429 | 1,373 | 1,412 | 1,530 | 1,648 | 1,695 | 1,746 |
| Operating Profit | 85 | 92 | 106 | 94 | 124 | 133 | 136 | 131 | 149 | 159 | 169 | 133 |
| OPM % | 6% | 6% | 7% | 6% | 8% | 8% | 9% | 8% | 9% | 9% | 9% | 7% |
| Other Income | 10 | 10 | 10 | 9 | 12 | 13 | 16 | 15 | 17 | 18 | 21 | 20 |
| Interest | 24 | 24 | 25 | 25 | 25 | 26 | 27 | 27 | 29 | 31 | 33 | 33 |
| Depreciation | 55 | 57 | 59 | 60 | 63 | 62 | 64 | 66 | 69 | 73 | 76 | 78 |
| Profit before tax | 16 | 20 | 32 | 18 | 48 | 57 | 61 | 53 | 69 | 73 | 80 | 42 |
| Tax % | 12% | 31% | −5% | 19% | 19% | 19% | 16% | 20% | 19% | 21% | 20% | 21% |
| Net Profit | 15 | 14 | 34 | 14 | 39 | 46 | 51 | 42 | 56 | 58 | 64 | 33 |
| EPS in Rs | 1.22 | 1.15 | 2.79 | 1.2 | 3.24 | 3.83 | 4.29 | 3.54 | 4.63 | 4.82 | 5.33 | 2.76 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 15%
- 5 Years
- 18%
- 3 Years
- 15%
- TTM
- 17%
- 10 Years
- 37%
- 5 Years
- 28%
- 3 Years
- 66%
- TTM
- 18%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −10%
- TTM
- —
- 10 Years
- 8%
- 5 Years
- 7%
- 3 Years
- 8%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| MedPlus Health Services | ₹ 610.60 | ₹ 7,182 Cr. | 34x | 3.6x | 12% | — |
| Novelix Pharmaceuticals | ₹ 60.99 | ₹ 166 Cr. | 52.3x | 2.9x | 8% | 1.9% |
| Muller & Phipps India Ltd | ₹ 195.00 | ₹ 12 Cr. | — | — | — | −0.9% |
Management
- Gangadi Madhukar Reddy
- Executive Chairman of the Board, Chief Executive Officer, Managing Director
- Sujit Kumar Mahato
- Chief Financial Officer
- Cherukupalli Bhaskar Reddy
- Chief Operating Officer, Whole-time Director
- Subrahmanyam Sharma Tatapudi
- Chief Technology Officer
- Manoj Kumar Srivastava
- Head - Corporate Secretarial, Compliance Officer, Company Secretary
- Kandasamy Vairaperumal
- Head of Supply Chain
Prices are delayed and for information only. Nothing on this page is investment advice.